Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
MediciNova is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for neurological, inflammatory, and fibrotic diseases. The company has no commercial products or revenue, operating as a pure R&D entity with lead candidates MN-166 (ibudilast) for progressive multiple sclerosis and substance use disorders, and MN-001 (tipelukast) for idiopathic pulmonary fibrosis and nonalcoholic steatohepatitis. With a $100M market cap, negative cash flow of approximately $13.5M annually, and a 9.86x current ratio, the company is entirely dependent on clinical trial outcomes and capital markets access for survival.
MediciNova operates a capital-intensive, binary-outcome business model typical of clinical-stage biotechnology. The company in-licenses or acquires drug candidates that have completed early development, then funds Phase 2/3 trials to demonstrate efficacy. Value creation occurs through positive clinical readouts that enable either: (1) out-licensing to larger pharmaceutical companies for milestone payments and royalties, (2) partnership deals with upfront payments, or (3) eventual commercialization. With minimal fixed infrastructure and outsourced clinical operations, the company burns approximately $13-15M annually on trial execution, regulatory activities, and G&A. The business has no pricing power until regulatory approval, at which point reimbursement negotiations with payers determine commercial viability. Current cash position of approximately $132M (based on 9.86x current ratio and minimal liabilities) provides roughly 9-10 years of runway at current burn rate, though this assumes no additional capital raises or trial expansions.
MN-166 Phase 3 trial data readouts for progressive multiple sclerosis (primary endpoint: disability progression measured by EDSS)
MN-166 clinical updates for methamphetamine and alcohol use disorders (FDA engagement on regulatory pathway)
MN-001 Phase 2 data for idiopathic pulmonary fibrosis (FVC decline as primary endpoint) and NASH (liver histology improvements)
Partnership or licensing announcements with major pharmaceutical companies (milestone payments, royalty structures)
FDA regulatory feedback on trial designs, endpoints, or approval pathways
Capital raises or financing announcements (dilution risk vs. runway extension trade-off)
Binary clinical trial risk: Single failed Phase 3 readout for MN-166 or MN-001 could eliminate 50-80% of market value overnight, as company has no revenue or approved products to cushion impact
Regulatory pathway uncertainty: FDA standards for progressive MS and substance use disorders continue evolving, with potential for endpoint rejection or additional trial requirements that extend timelines by 3-5 years
Competitive obsolescence: Biogen's Tysabri, Novartis' Gilenya, and emerging BTK inhibitors for progressive MS create high efficacy bars; MN-166 must demonstrate differentiated safety/efficacy profile to justify market entry post-2028
Progressive MS landscape increasingly crowded with Roche's ocrelizumab, Novartis' siponimod, and multiple BTK inhibitors in late-stage development offering potentially superior efficacy
Substance use disorder space sees competition from behavioral interventions, existing generics (naltrexone, buprenorphine), and well-funded competitors with faster regulatory timelines
Larger pharmaceutical companies can out-spend on trial recruitment, access better clinical sites, and leverage existing commercial infrastructure for faster market penetration post-approval
Dilution risk: With $13.5M annual burn and no revenue, company will require additional equity raises within 9-10 years if trials extend or expand, potentially diluting existing shareholders by 30-50%
Capital markets access risk: Biotech financing windows are cyclical and sentiment-driven; inability to raise capital during risk-off periods could force asset sales, trial delays, or bankruptcy despite strong cash position today
Negative ROE of -24.9% and ROA of -36.2% reflect ongoing cash consumption with no near-term path to profitability, making the company entirely dependent on clinical catalysts to justify valuation
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. Patient enrollment may see modest impacts during severe recessions if healthcare access declines, but neurological and fibrotic diseases are non-discretionary conditions. The company's burn rate is contractually committed to CROs and remains stable regardless of economic conditions. However, the ability to raise capital is highly sensitive to risk appetite in biotech equity markets, which correlates with broader economic confidence.
Rising interest rates negatively impact MediciNova through two channels: (1) Higher discount rates compress the present value of distant, uncertain future cash flows from potential drug approvals, disproportionately affecting pre-revenue biotechs with 5-10 year commercialization timelines. (2) Rate increases reduce investor appetite for speculative, cash-burning equities as safer fixed-income alternatives become attractive. The company holds cash in short-term instruments, providing modest offset through higher interest income, but this is immaterial relative to valuation compression. A 100bp rate increase typically contracts biotech valuations by 10-15%.
minimal - The company has negligible debt (0.01x debt/equity) and does not rely on credit markets for operations. However, the ability to access equity capital markets is critical for long-term survival. Credit spread widening signals risk-off sentiment that closes IPO/follow-on windows for biotechs, forcing companies to accept dilutive terms or delay trials. High-yield spreads above 500bp historically correlate with biotech financing droughts.
growth - Attracts speculative biotech investors seeking asymmetric returns from binary clinical catalysts. Typical holders include specialized healthcare hedge funds, biotech-focused mutual funds, and retail investors with high risk tolerance. Not suitable for value or income investors given zero revenue, negative cash flow, and no dividend. The investment thesis is purely event-driven: positive Phase 3 data could generate 200-500% returns, while failure results in 60-80% drawdowns. Momentum traders enter around data readout announcements.
high - Clinical-stage biotechs with single-digit revenue multiples and binary trial outcomes exhibit 60-80% annualized volatility. Stock experiences 20-40% single-day moves on clinical data releases, FDA announcements, or partnership news. Beta to broader market is low (0.3-0.5) as stock-specific catalysts dominate, but correlation to biotech sector (XBI) is high (0.7-0.8). The -16.7% one-year return with +22.1% six-month return illustrates event-driven volatility patterns.
